BML-210 is a novel HDAC inhibitor, and its mechanism of action has not been characterized.
IC50 value: 5 μM[1]
Target: HDAC4
In vitro: Cell cycle analysis indicated that HeLa cell treatment with 20 and 30 μM concentration of BML-210 increased the proportion of cells in G0/G1 phase, and caused accumulation in subG1, indicating that the cells are undergoing apoptosis[2]. BML-210 inhibits the growth of NB4 cells in dose- and time-dependent manner[3].
In vivo:
IC50&Target
HDAC4:MEF2
分子式
C20H25N3O2
分子量
339.43
CAS号
537034-17-6
运输条件
Room temperature in continental US; may vary elsewhere.